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Summary Mice transplanted with NC carcinoma were treated with the thromboxane synthetase inhibitor
dazmegrel (UK38485) or with nafazatrom (BAY G 6575), a compound that is reported to increase
prostacyclin formation. Some experiments included the cytotoxic drugs methotrexate and melphalan. The
tumours were excised under anaesthesia on day 14 or day 21 after transplanation, and weighed; some were
extracted for prostanoids which were measured by radioimmunoassay. Mouse survival time was determined
up to day 121, and cancer spread was determined by postmortem examination. The survival was increased by
methotrexate and melphalan but not by the other drugs. Nafazatrom-treated mice tended to have lighter
tumours. Although dazmegrel reduced the formation of thromboxane B2 during clotting of blood from
normal mice, it did not affect the tumour yields of prostanoids. Nafazatrom had no effect on serum or
tumour prostanoids. There were no obvious effects of the treatments on the recurrence of tumour in the
excision scar, lung metastasis or spread to lymph nodes.
Effects of the arachidonate metabolites throm-
boxane A2 (TXA2) and prostacyclin (PGI2) on
platelet aggregation are well known. The ability of
TXA2 produced by platelets to cause their
aggregation may normally be balanced by PGI2
which is inhibitory (Moncada & Vane, 1979).
Platelet aggregation is thought to be important in
the haematogenous spread of some tumours, and
Honn (1982) and his colleagues (Honn et al., 1981,
1983) suggested that circulating tumour cells, or
vesicles shed from the primary tumour cells, disrupt
the balance between PGI2 and TXA2 in favour of
platelet aggregation. Experiments with intra-
venously injected B-16a melanoma cells showed
that thromboxane synthesis inhibitors, PGI2, or
nafazatrom (which has various actions including an
increase of PGI2 formation), are antimetastatic
(Honn, 1982; Honn et al., 1983). A thromboxane
synthesis inhibitor also reduced spontaneous metas-
tasis from Lewis lung carcinoma (Honn, 1982).
Furthermore, Donati ft al. (1982) found that
tumour cells which produced highest amounts of
TXA2 were most metastatic in mice. However, it is
not known to what extent this applies to other
tumours, and no studies relating to this question
have been reported previously on survival of
tumour-bearing animals.
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Drugs that inhibit cyclo-oxygenase usually reduce
the size of NC tumours, and prolong host survival
when given alone or with the cytotoxic drugs
methotrexate and melphalan (Bennett et al., 1979,
1982). Cyclo-oxygenase inhibitors reduce both
thromboxane and prostaglandin formation, but it is
not known if the effect on thromboxane production
contributes to the effects of indomethacin and
flurbiprofen on tumour size and mouse survival.
The aims of the present study were: (i) to
examine Honn's hypothesis, using nafazatrom or
the thromboxane synthetase inhibitor dazmegrel in
the mouse NC tumour model, (ii) to measure
mouse survival time, tumour weight and prostanoid
content and (iii) to study the effect of dazmegrel in
combination with cytotoxic drugs.
Materials and methods
The NC carcinoma used in these studies originally
arose spontaneously in the mammary region of a
WHT/Ht mouse (Hewitt et al., 1976), the same
strain used in our experiments. Following local
excision of this carcinoma there is a high incidence
of local lymphatic spread, recurrence in the excision
scar, and metastasis mainly to the lungs and
mediastinum.
The mice were fed SDS No. 1 modified diet and
had free access to water. On day 0, female
WHT/Ht mice were injected s.c. into the left flank
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with 106 NC carcinoma cells prepared as
described previously (Bennett et al., 1979, 1982).
All drugs were given by mouth in 0.1 ml 50% syrup
B.P. without preservative, pH 7.8. There were 8,
separate experiments with the thromboxane
synthetase inhibitor dazmegrel (UK38485; Parry et
al., 1982), each with 7-15 mice/group treated as
shown in Table I. Methotrexate 2.0mgkg- and
melphalan 1.4mgkg-1 were given together on days
15-17, 22-24, 29-31 to some of the mice given
dazmegrel or no other treatment.
The transplanted tumours were excised under
ether anaesthesia on day 14 or day 21 and weighed.
Some were cut finely, washed with Krebs solution
and homogenised in Krebs solution/ethanol (50:50)
acidified to -pH3 with formic acid. They were
then extracted prior to radioimmunoassay (Hennam
et al., 1974) for PGE, 6-keto-PGF1 and TXB2.
The cross-reactions of the antibodies were as
follows (%): PGE antibody (Miles Scientific), PGE2
100; PGE1 53; PGF2a 10; PGA1 2.7; PGFia 2.6;
PGB2 1.5; PGA2 1.4; PGB1 0.9. 6-Keto-PGF1,
antibody (Wellcome Research Laboratories), 6-
keto-PGF1. 100; PGF2a 3.0; PGE2 0.1; TXB2 0.02.
TXB2 antibody (Wellcome Research Laboratories),
TXB2 100; PGF2a 0.11; 6-keto-PGF1a 0.01; PGE2
<0.01. Intra- and inter-assay coefficients of
variation were respectively 10-11% and 15-21%,
and the lower limits of detection were (pg 100yIl 1):
PGE 15.6; 6-keto-PGF1, 12.5; TXB2 7.8. The
tritated compounds, obtained from Amersham
International, had the following specific activities
(TBqmmol-1): PGE2 5.92; 6-keto-PGF1a 5.55;
TXB2 6.66. The bound and unbound compounds
were separated by adding 1 ml of cold (4°C)
ammonium sulphate/calcium sulphate (65%
saturated ammonium sulphate solution pH 7.6 +
calcium sulphate 1 g25ml-1, maintained as an even
suspension with a magnetic stirrer).
Table I Regimen offreatment
Drug Micel
Daily treat- Day of group
dose ment tumour No. in each
Drugs mgkg -I begun excision expts. expt.
Dazmegrel 50x2 DI D14 3 10-14
Dazmegrel 50 x 2 D13 D14 2 10
Dazmegrel 50 x 2 D20 D21 1 10
Dazmegrel 5 x 2 D20 D21 2 7-15
Nafazatrom 1 and 2 D-1 D14 1 10
Nafazatrom 1 and 2 D-1 D21 2 9-15
Nafazatrom 2 D-1 D21 1 15
Tumour was inoculated on day 0, and treatment with
nafazatrom started the previous day (D- 1). Vehicle
controls were carried out for each experiment. These
treatments were given 5 days/week (Monday to Friday),
and groups received methotrexate and melphalan as de-
scribed in the text.
In 4 other experiments, each with 10-15 female
mice/group, nafazatrom 1 or 2mgkg-1 was given
daily by mouth in 0.1 ml 50% syrup. Treatment
started on the day prior to tumour transplantation
and continued until death or the end of the
experiment. The tumours were excised on day 21
and weighed. Some other tumours were homo-
genised and extracted for determination of
prostanoids by radioimmunoassay as described
above.
Body weights were measured twice-weekly
throughout the experiments, starting from at least 2
weeks prior to tumour transplantation. Mice with
advanced carcinomatosis or those who survived the
duration of the experiments were killed humanely
to prevent suffering (Bennett et al., 1982). Mouse
Table II Radioimmunoassay of mouse serum prostanoids
Drug mgkg-1 PGE n TXB2 n 6-keto-PGF1c, n
Control 0 66 (46-84) 8
Dazmegrel 5 22 (19-30)c 8
Control 0 5 (4-6) 4 70 (67-160) 7 5 (3-7) 6
Dazmegrel 50 44 (38-52)b 6 13 (11-15)b 8 14 (11-17)a 8
Control 0 7 (6-7) 7 170 (160-180) 8 3 (2-5) 8
Nafazatrom 1 6 (5-7) 7 160 (120-180) 8 3 (3-4) 7
Control 0 20 (12-49) 6 130 (110-150) 7 7 (< 1-22) 7
Nafazatrom 2 7 (5-11) 5 130 (110-150) 6 14 (6-20) 6
All samples were collected via cardiac puncture 2h after dosing. 0 represents vehicle
controls. Results are ngml-1, shown as median values with semiquartile ranges in
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survival time was measured from the day ol tumour
transplantation until death. The incidences of scar
recurren'ce, lymph node involvement and distant
metastases were noted at postmortem. Survival was
analysed statistically by the method of Lee and
Desu (1972), and the other data were analysed by
the Mann-Whitney U-test or, where specified,
Fisher's exact test.
There were initial experiments using WHT/Ht
mice without tumours to determine the effects of
the drugs on blood prostanoids. The mice were
given dazmegrel 5 or 50 mgkg- 1 twice daily,
nafazatrom 1 or 2 mgkg-1 once daily, or vehicle
(4-8 mice/group). On the second day blood was
obtained by cardiac puncture 2h after the last dose.
Following incubation at 37°C for 30min, to allow
formation of TXB2, the samples were centrifuged
(1500g, 4°C for 10min) and the serum stored at
-20°C until radioimmunoassay of the unextracted
samples for TXB2, PGE and 6-keto-PGFI.
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Figure 1 The weights of tumours excised on day 14
(the 2 left-hand groups of columns) were apparently
unaffected by dazmegrel or nafazatrom. However,
tumours excised on day 21 (right-hand groups of
columns) were smaller when mice were treated with
nafazatrom lmgkg1 (P<0.003) or 2mgkg-1
(P =0.03). C, vehicle control; D, dazmegrel
50mgkg-1; Nl and N2, nafazatrom 1 and 2mgkg-1.
Each column represents the median, with the
semiquartile range shown as a bar. The numbers of
mice in each group, starting with the left-hand column,
were: 54, 50, 10, 10, 10, 25, 25, 40 and 35.
Results
Tumour weights
All these experiments were with female mice.
Transplanted tumours were palpable by day 10,
and then grew quickly. With day 14 excision the
tumour weights were similar to controls in mice
treated with dazmegrel 50mgkg-1 from day 1 or
day 13 (P>0.5; Figure 1; day 13 data not shown).
In contrast, the tumours excised at day 21 from
female mice given nafazatrom 1 or 2mgkg-1 from
the day prior to transplantation were lighter than
controls (P<0.003 and 0.03 respectively, Figure 1).
Serum prostanoids
Serum from blood removed 2h after the last dose
of dazmegrel 5 or 50 mgkg- 1 contained less TXB2
and more 6-keto-PGF1 and PGE than controls
(Table II). Nafazatrom 1 or 2mgkg- 1 did not
affect the amounts of serum prostanoids.
Tumour prostanoids
Dazmegrel or nafazatrom had little or no effect on
the tumour yields of 6-keto-PGF1a, PGE or TXB2
(Figure 2).
Survival, tumour weight and recurrence
Dazmegrel did not confer any benefit on survival,
regardless of the dose, the time of starting
treatment, or the time of tumour excision (Table
III; Figure 3).
Table III Mouse survival (shown as median days, with semiquartile ranges in parentheses)
Treated
Drug mgkg 1 from Controls Drug-treated Cytotoxics Drug+cytotoxics
Dazmegrel 50 x 2 Dl 39 (35-48) n=34 42 (38-55) n=30 51 (44-57) b, d n=20 50 (43-63) b, c n=20
Dazmegrel 50x2 D13 45(41-51)n=20 48(41-57)n=20 55(48-69)b,cn=19 52(42-64) n=20
Dazmegrel 5 x 2 D20 43 (41-48) n= 17 42 (39-46) n=20 50 (49-63) b, d n=20 56 (49-63) b, d n=25
Dazmegrel 50x2 D20 44(43-46) n=9 43(39-44) n=9 49(49-51) a, d n= 10 48 (44-50) d n_=10
Nafazatrom 1 D-1 43 (42-49) n= 15 47 (47-50) n= 15
Nafazatrom 2 D-1 49 (43-52) n=29 50 (47-54) n=24
Treatment was started on the day (D) shown and continued until death. The cytotoxics were methotrexate 2mgkg-1
and melphalan 1.4mgkg-1. P values were: a=0.02, b<0.01 compared to controls; c=0.07, d<0.05 compared to
dazmegrel. In some cases the P values for b and d are substantially lower than shown but, to aid simplicity, they are not
specified. Othe values were P>0.1.260 I.F. STAMFORD et al.
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Figure 2 The amounts of prostanoids from tumours excised on day 14 (the 6 left-hand groups) or day 21
(the 3 right-hand groups) were apparently unaffected by dazmegrel or nafazatrom. C, vehicle controls; D,
dazmegrel 50mgkg-1; NI and N2, nafazatrom 1 and 2mgkg-'. Each column represents the median, with
the semiquartile range shown as a bar. The numbers of mice in each group, starting with the left-hand 6
columns, were: 13, 9, 31, 26, 18, 16; the others had 10/group. E, prostaglandin E2; 6-K, 6-keto-prostaglandin
Fl.; TX, thromboxane B2. All comparisons with respective controls were P>0.1.
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Figure 3 Dazmegrel (dotted lines) had little or no effect on the survival of mice with resected tumours
compared with vehicle controls (solid lines). Percent survival is shown on the vertical axis, and days on the
horizontal axis. A: dazmegrel 50mgkg-1 from day 13, tumour excised on day 14, P=0.8. B: dazmegrel
50mgkg-1 from day 1, excision day 14, P=0.2. C: dazmegrel 50mgkg-1 from day 20, excision day 21,
P=0.15. D: dazmegrel Smgkg-I from day 20, excision day 21, P=0.7.
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Recurrence at the excision site seemed to be
unaffected by dazmegrel, and the postmortem
findings revealed no obvious effects on lung
metastasis or spread to lymph nodes, regardless of
the dose or timing of the treatment (Table IV).
Methotrexate 2mgkg- given with melphalan
1.4mgkg- 1 increased survival, but addition of
dazmegrel made little or no further difference
(Table III).
Nafazatrom 1 or 2mgkg1 did not alter survival
(Figure 4), spread to lymph nodes, or lung
metastasis (Table IV). The drug was not examined
in combination with the cytotoxic drugs.
Discussion
The experiments with mouse serum ex vivo showed
that the thromboxane synthetase inhibitor
dazmegrel reduced thromboxane formation during
blood clotting. There were also increased amounts
of serum 6-keto-PGF1. and PGE, presumably due
to diversion of substrate metabolism.
The inhibition of thromboxane synthesis would
be expected to reduce the formation of platelet
aggregates around tumour cells released into the
bloodstream and, according to Honn's hypothesis,
to reduce metastatic spread.
We obtained no evidence from the survival or
postmortem data of an anti-cancer effect of
dazmegrel. However, our experiments differ from
those of Honn et al. (1981) and Honn (1982) in the
types of tumour and thromboxane synthesis
inhibitors, and in the method of assessment. They
counted lung metastases after a fixed time (mainly
following the intravenous injection of cancer cells),
whereas we measured mainly survival and
postmortem findings. Most of their experiments
were with the B-16a melanoma whereas our tumour
is a metastasizing adenocarcinoma originally of
spontaneous origin. We chose a different
thromboxane synthesis inhibitor, partly because
dazmegrel is suitable for human use (Fischer et al.,
1983). Our studies with platelet thromboxane
synthesis confirm that this drug is also active in
mice.
Table IV NC tumour spread (postmortem data)
Treat Lymph Scar Lung
Drug mgkg-1 from Excision nodes recurrence metastases
Control 0 DI D14 27/34 20/34 22/34
Dazmegrel 50 x 2 Dl D14 22/30 17/30 20/30
Cytotoxics D14 17/20 11/20 14/20
Dazmegrel
+cytotoxics 50 x 2 Dl D14 12/20 4/20a 14/20
Control 0 D13 D14 13/20 8/20 17/20
Dazmegrel 50 x 2 D13 D14 13/20 4/20 17/20
Cytotoxics D14 13/18 7/18 15/18
Dazmegrel
+cytotoxics 50 x 2 D13 D14 10/20 8/20 14/20
Control 0 D20 D21 9/9 5/9 8/8*
Dazmegrel 50 x 2 D20 D21 7/8 3/8 7/8
Cytotoxics D21 8/10 7/10 10/10
Dazmegrel
+cytotoxics 50 x 2 D20 D21 7/9* 4/9* 9/9*
Control 0 D20 D21 11/17 12/17 13/17
Dazmegrel 5 D20 D21 14/20 16/20 18/20
Cytotoxics D21 14/20 8/20 17/20
Dazmegrel
+cytotoxics 5 D20 D21 18/25 11/25 23/25
Control 0 D-1 D21 15/15 5/15 15/15
Nafazatrom 1 D-1 D21 14/15 5/15 14/15
Control 0 D-1 D21 19/29 17/29 29/29
Nafazatrom 2 D-1 D21 16/24 17/24 21/24
Treatment was started on the day (D) shown and continued until death. Cytotoxics,
methotrexate 2mgkg-1 and melphalan 1.4mgkg-1 given on days 15-17, 22-24 and
29-31. Controls were given 50% syrup. a, P=0.02; all other comparisons P>0.1, but
since the cytotoxics lengthened survival the tumour had longer to spread. *One not scored.262 I.F. STAMFORD et al.
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Figure 4 Nafazatrom (dotted lines) had little or no
effect on the survival of mice with resected tumours
compared with vehicle controls (solid lines). Percent
survival is shown on the vertical axis, and days on the
horizontal axis. a and b, nafazatrom 1 and 2mgkg-1
respectively from the day before tumour
transplantation, tumour excision on day 14, P=0.2
and 0.4.
Perhaps the failure to alter metastasis via an
effect on platelets might have been because the
inhibition was not sufficiently strong or long-
lasting, or that diversion of blood prostanoid
synthesis to PGI2 or PGE2 counteracts any benefit
that might result from inhibition of thromboxane
synthesis. Alternatively, it may be that inhibition of
platelet thromboxane synthesis does not affect the
spread of NC tumour. If so, the increase of survival
by indomethacin or flurbiprofen in mice with this
tumour (Bennett et al., 1982) is by a different
action. Another factor may be that dazmegrel did
not inhibit tumour thromboxane synthesis. This
was surprising because dazmegrel is classified as a
thromboxane synthesis inhibitor and acts as such in
mouse blood ex vivo. However, Patrono et al.
(1984) found that although dazoxiben and other
drugs given to human subjects greatly reduced
platelet thromboxane formation, they had only a
weak effect on kidney thromboxane formation.
Furthermore, Stork and Dunn (1985) reported that
although the thromboxane synthetase inhibitor
OKY-1581 abolished the increase of rat glomerular
thromboxane production in response to nephrotoxic
serum ex vivo, the drug had little effect on basal
levels. It may be relevant that the amounts of
prostanoids which we obtained by homogenising
tumours in acid-ethanol approximate to basal levels
(Bennett et al., 1973). Honn (1982) did not measure
prostanoids, so that we do not know if our lack of
effect on tumour thromboxane formation explains
the difference from his findings on metastasis. Nor
can we deduce whether the reduction of tumour
weight by indomethacin or flurbiprofen (Bennett et
al., 1979, 1982) involves inhibition of thromboxane
synthesis.
As we have previously reported (Bennett et al.,
1982, 1985), indomethacin, flurbiprofen, or
methotrexate+melphalan prolong the survival of
mice with excised transplanted NC tumours. This
prolongation is greater when indomethacin or
flurbiprofen are given together with the cytotoxic
drugs. Dazmegrel given alone or with
methotrexate+melphalan did not alter mouse
survival. Apart from the lack of effect on tumour
thromboxane synthesis, no alteration of survival
would necessarily be anticipated with a throm-
boxane synthesis inhibitor since the prolongation
with indomethacin seems to be prostaglandin-
mediated; the effect of indomethacin was counter-
acted by giving a long-acting PGE2 analogue
(Bennett et al., 1985).
Nafazatrom is reported to inhibit lipoxygenase
activity and increase PGI2 production, and was
found by Honn et al. (1983) to reduce the
formation of lung metastases in mice injected with
B-16a melanoma cells. However, we found no effect
of the drug on the serum or tumour prostanoid
content or host survival, although nafazatrom-
treated mice tended to have smaller tumours. The
lack of effect on survi'Val is consistent with the
failure of nafazatrom to sffect serum or tumour
prostanoids, but again we do not know if this
explains the difference from the results of Honn et
al. (1983) since they did not measure prostanoids.
We therefore conclude that neither nafazatrom nor
the thromboxane synthetase inhibitor dazmegrel are
anticancer in the mouse NC tumour model. Our
evidence argues against an important role for blood
TXA2 and PGI2 in the spread of mouse NC
carcinoma, but since the drugs did not affect
tumour prostanoid synthesis no firm conclusion can
be reached about roles of thromboxanes or PGI2 in
tumour growth.
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